Skip to main content

Table 3 Duration of Response (Days)

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Response

 

Cohort 1

Cohort 2

Complete Response

Mean (SD)

84 (93.8)

–

Median

56

–

Range

8–189

(ongoing)

Partial Response

Mean (SD)

194 (180.0)

113 (103.0)

Median

118

133

Range

77–512

1–204

Stable Disease

Mean (SD)

125 (156.8)

127 (186.3)

Median

56

63

Range

1–509

1–544